Initial and the second-line treatment options for graft-vs-host disease, and a review of the REACH-1 trial and approval of ruxolitinib.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
![](https://i.ytimg.com/vi/XkeNDxkjpPk/maxresdefault.jpg)
Initial and the second-line treatment options for graft-vs-host disease, and a review of the REACH-1 trial and approval of ruxolitinib.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]